15 April 2024
15 April 2024
SK Life Sciences Xcopri (cenobamate) is approved as an oral suspension mixed with water for mouth administration or via a nasogastric tube.
As the UK tackles several drug shortages, UK charities and pharmacists called for urgent action to be taken.
The FDA designation follows positive Phase II data announced recently.
Nigeria is the first country to introduce a vaccine against five meningitis strains.
The recall of the bottles of high blood pressure medication in the US was due to non-compliance with dissolution standards.
Century will pay $35m upfront and an additional $10m milestone payments to acquire Clade Therapeutics.
PIVLAZ is set to launch in South Korea early next year.
The agency issued the recall due to quality concerns after NAFDAC detected a toxic substance in the medicine.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report offers insight into the competitive landscape of leading CGT agents in CNS disorders including launch date projections, analyst consensus forecasts, LoA analysis, and commentary on current and future players. The global CGT market in CNS disorders will experience significant growth, with sales expected to grow at a CAGR of 42.4% by 2029. Gene therapies will dominate the CGT market in CNS disorders, attributed to strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively.
GlobalData's latest report offers insight into the competitive landscape of leading CGT agents in CNS disorders including launch date projections, analyst consensus forecasts, LoA analysis, and commentary on current and future players. The global CGT market in CNS disorders will experience significant growth, with sales expected to grow at a CAGR of 42.4% by 2029. Gene therapies will dominate the CGT market in CNS disorders, attributed to strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively.
Give your business an edge with our leading industry insights.
